MARKET

IRWD

IRWD

Ironwood
NASDAQ
6.48
-0.16
-2.41%
After Hours: 6.48 0 0.01% 19:00 05/17 EDT
OPEN
6.64
PREV CLOSE
6.64
HIGH
6.68
LOW
6.47
VOLUME
1.47M
TURNOVER
0
52 WEEK HIGH
15.70
52 WEEK LOW
6.21
MARKET CAP
1.03B
P/E (TTM)
-0.9546
1D
5D
1M
3M
1Y
5Y
Ironwood Pharmaceuticals’ (NASDAQ:IRWD) Challenges Continue with Q1 Misses
TipRanks · 5d ago
Weekly Report: what happened at IRWD last week (0506-0510)?
Weekly Report · 6d ago
Ironwood Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 17:13
Ironwood Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Dow Jones · 05/10 16:37
Ironwood Pharmaceuticals Price Target Cut to $14.00/Share From $18.00 by Craig-Hallum
Dow Jones · 05/10 16:37
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
Benzinga · 05/10 16:26
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
NASDAQ · 05/10 15:16
Ironwood Pharmaceuticals First Quarter 2024 Earnings: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)
Ironwood Pharmaceuticals's revenue is forecast to grow 12% p.a. On average during the next 3 years. The company's shares are down 19% from a week ago. Revenue is down 28% from 1Q 2023 and the company's net loss is down 109%. The company has 4 warning signs for investors to be aware of.
Simply Wall St · 05/10 13:06
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.